Relvar

Type: Product
Name: Relvar
First reported Aug 21 2014 - Updated Aug 22 2014 - 1 reports

Theravance to Present at the Baird 2014 Health Care Conference

- Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Theravance's President and Chief Executive Officer, is scheduled to present at the Baird 2014 Health Care Conference on Thursday, September 4, 2014, at 10:50 a.m. EDT. The conference ... [Published I Stock Analyst - Aug 21 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 2 reports

Theravance Biopharma: Neglected Spinoff Targeting A Huge Underserved Market

By Virginia Value Investor :Theravance (NASDAQ: THRX ) is probably a familiar name to many of you. The pharmaceutical company has received extensive coverage on Seeking Alpha over the years. What's surprising is how little attention their recent spin ... [Published BioPortfolio - Aug 21 2014]
First reported Aug 19 2014 - Updated Aug 19 2014 - 1 reports

Vectura Group plc : Interim Management Statement

Vectura Group plcInterim Management StatementChippenham, UK - 19 August 2014:Following the acquisition of Activaero GmbH in March 2014, the integration of the business is progressing well and Vectura's product pipeline is progressing in line with the ... [Published Investegate - Aug 19 2014]
First reported Aug 15 2014 - Updated Aug 15 2014 - 1 reports

AWMSG recommends GSK’s Relvar Ellipta to treat asthma

All Wales Medicines Strategy Group (AWMSG) has recommended British drug-maker GlaxoSmithKline's (GSK) Relvar Ellipta to treat patients with asthma within NHS Wales, following the receipt of ministerial ratification.Relvar Ellipta was granted a license ... [Published Pharmaceutical Technology - Aug 15 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Human medicines European public assessment report (EPAR): Relvar Ellipta, fluticasone furoate / vilanterol, Revision: 1, Authorised

Entities: Relvar, Ellipta
First reported Aug 12 2014 - Updated Aug 12 2014 - 1 reports

Theravance Posts 2nd Quarter Financial Results

Theravance reported financial results for the quarter ended June 30, and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on September 18, to stockholders of record as of the close of business on August 28. According ... [Published Individual.com - Aug 12 2014]
First reported Aug 06 2014 - Updated Aug 07 2014 - 4 reports

Theravance, Inc. Reports Second Quarter 2014 Financial Results

(Marketwired via COMTEX) -- Theravance, Inc. THRX +1.20% today reported financial results for the quarter ended June 30, 2014 and announced that its Board of Directors approved a $0.25 per share cash dividend to be paid on September 18, 2014 to stockholders ... [Published BioSpace - Aug 07 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Asthma Therapeutics Market 2019: Worldwide Business Survey

Market Research, a leading business intelligence provider, has released its latest research report “Asthma Market to 2019”. The asthma market is forecast to grow marginally over the forecast period across the leading eight developed nations, from $16.6 ... [Published MyNewsDesk - Aug 01 2014]
Entities: Asthma, Therapeutics, Market
First reported Jul 29 2014 - Updated Jul 29 2014 - 1 reports

Theravance to Report Second Quarter 2014 Financial Results on August 6, 2014

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/29/14 -- Theravance, Inc. ( NASDAQ: THRX ) announced today that it will release financial results for the period ended June 30, 2014 after market close on Wednesday, August 6, 2014.An accompanying conference ... [Published CEOWorld Magazine - Jul 29 2014]
First reported Jul 24 2014 - Updated Jul 25 2014 - 2 reports

Theravance Downgraded to Neutral at Morgan Stanley (THRX)

The analysts wrote, “Following comments from GSK on its 2Q14 results call on continued pressure on the branded COPD market from competitor discounting (resulting in challenging formulary coverage), we lowered our near and longer term sales expectations ... [Published American Banking News - Stock Ratings - Jul 24 2014]
First reported Jul 24 2014 - Updated Jul 24 2014 - 5 reports

Surveyed EU5 Pulmonologists Expect that Relvar, the First Once-Daily LABA/ICS FDC, Will Experience Healthy Uptake in Asthma

/PRNewswire/ -- finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first once-daily long-acting beta2 agonist/inhaled corticosteroid ... [Published Freshnews.com - Jul 24 2014]
Entities: Relvar, Asthma, Experience
First reported Jun 11 2014 - Updated Jun 12 2014 - 1 reports

GSK and Theravance Announce Positive Data From Two Studies Evaluating the Efficacy and Safety of Incruse(TM) Ellipta(R) When Added to Relvar(R)/Breo(R) Ellipta(R) in Patients With COPD

LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 11, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from two phase III studies, which showed that patients ... [Published Marketwire - Breaking News Releases - Jun 11 2014]

Quotes

...On earnings calls they typically refer to this as the " triple therapy ". It combines an inhaled corticosteroid (used to control asthma), a long acting muscanrinic antagonist (for COPD) and a long acting beta2-adrenergic agonist (for muscle relaxation)."
"During the period we have made excellent progress with our generic programmes and we now have the support of our existing partner for VR315 in the US to help us bring VR506 to the market in an expeditious manner. With our strong cash balance and our new royalty revenues, along with the royalties received from the excellent progress of Seebri® Breezhaler® and Ultibro® Breezhaler®, Vectura is well positioned to continue its transition towards creating a leading specialty pharmaceutical company focused on airways disease." Vectura Group plc
...the goal of building a company focused on generating returns for our stockholders," said Rick E Winningham, Chief Executive Officer of Theravance . "Over the last twelve years, the Theravance and GSK partnership has worked together to bring two important medicines, RELVAR/BREO and ANORO ELLIPTA, to the global respiratory market and are working on a pipeline of other important potential respiratory medicines still in development. I would like to extend my gratitude to the Theravance and GSK teams for their support, dedication and commitment to bringing important medicines to patients in need."
"This will provide clinicians with what we believe is an important option that will enable them to tailor treatment for individual patient needs."

More Content

All (42) | News (35) | Reports (0) | Blogs (6) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Theravance to Present at the Baird 2014 Health ... [Published I Stock Analyst - Aug 21 2014]
Theravance Biopharma: Neglected Spinoff Targeti... [Published BioPortfolio - Aug 21 2014]
Theravance Biopharma: Neglected Spinoff Targeti... [Published Seeking Alpha - Aug 21 2014]
Vectura Group plc : Interim Management Statement [Published Investegate - Aug 19 2014]
Theravance : Appoints Michael Aguiar as Preside... [Published 4 Traders - Aug 16 2014]
AWMSG recommends GSK’s Relvar Ellipta to treat ... [Published Pharmaceutical Technology - Aug 15 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 13 2014]
Theravance Posts 2nd Quarter Financial Results [Published Individual.com - Aug 12 2014]
Theravance (THRX) Incurs Narrower-than-Expected... [Published Zacks.com - Aug 08 2014]
Theravance, Inc. Reports Second Quarter 2014 Fi... [Published BioSpace - Aug 07 2014]
Theravance's (THRX) CEO Rick Winningham on Q2 2... [Published Seeking Alpha - Aug 07 2014]
South San Francisco's Theravance, Inc. Brings I... [Published BioSpace - Aug 06 2014]
Theravance, Inc. Appoints Michael W. Aguiar as ... [Published Market Pulse Navigator - Aug 06 2014]
Asthma Therapeutics Market 2019: Worldwide Busi... [Published MyNewsDesk - Aug 01 2014]
Theravance to Report Second Quarter 2014 Financ... [Published CEOWorld Magazine - Jul 29 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published Freshnews.com - Jul 24 2014]
Surveyed EU5 Pulmonologists Expect That Relvar,... [Published TheStreet.com - Jul 24 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published Securities Technology Monitor - Jul 24 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published RCL Advisors - Jul 24 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published PR Newswire: General Business - Jul 24 2014]
Theravance Downgraded to Neutral at Morgan Stan... [Published American Banking News - Stock Ratings - Jul 24 2014]
UPDATE: Bank Of America Downgrades Theravance A... [Published Benzinga.com - Jul 24 2014]
GlaxoSmithKline in free-fall [Published Interactive Investor - Jul 23 2014]
Theravance : GSK and Theravance Introduce Initi... [Published 4 Traders - Jul 22 2014]
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Marketwire - Breaking News Releases - Jul 02 2014]
Theravance, Inc. Appoints George B. Abercrombie... [Published Marketwire - Breaking News Releases - Jun 12 2014]
GSK and Theravance Announce Positive Data From ... [Published Marketwire - Breaking News Releases - Jun 11 2014]
Interim Management Statement [Published TrustNet - May 16 2014]
1st Quarter Results [Published TrustNet - Apr 30 2014]
Welcome tonic [Published Engineer Online - Apr 23 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Aug 13 2014]
Surveyed EU5 Pulmonologists Expect that Relvar,... [Published PR Newswire: General Business - Jul 24 2014]
BURLINGTON, Mass., July 24, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of asthma, pulmonologists in the EU5 countries (France, Germany, Italy, Spain and the United Kingdom) hold a generally positive view of the first ...
Theravance, Inc. Appoints Theodore J. Witek, Jr... [Published Marketwire - Breaking News Releases - Jul 02 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 2, 2014) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), A Royalty Management Company, today announced the appointment of Theodore J. Witek, Jr. as Senior Vice President Corporate Partnerships, Clinical ...
Theravance, Inc. Appoints George B. Abercrombie... [Published Marketwire - Breaking News Releases - Jun 12 2014]
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 12, 2014) - Theravance, Inc. (NASDAQ: THRX) ("Theravance"), a royalty management company, today announced the appointment of George B. Abercrombie, Senior Vice President, Corporate Partnerships, Commercial. ...
GSK and Theravance Announce Positive Data From ... [Published Marketwire - Breaking News Releases - Jun 11 2014]
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 11, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from two phase III studies, which showed that patients ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.